AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc.

Overview
Date Founded

2001

Headquarters

1 Broadway,14th floor,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

19

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at AVEO Pharmaceuticals Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President, Chief Executive Officer & Director

Chief Financial Officer & Principal Accounting Officer

Chief Medical Officer

Head-Regulatory Affairs

Senior Vice President-Commercial Operations & Business Analytics

Senior Vice President of Technical Operations & Quality Assurance

Vice President, Financial Accounting & Reporting

Vice President, Clinical Operations

Vice President, Medical Affairs

Vice President, Marketing

Board of Directors

Founder at RCY Medicine

President, Chief Executive Officer & Director at AVEO Pharmaceuticals Inc.

Chief Executive Officer at Antios Therapeutics, Inc.

Former President & Chief Executive Officer at NitroMed, Inc.

Former President & Chief Commercial Officer at VisionGate, Inc.

Former Research Analyst at Goldman Sachs International

Paths to AVEO Pharmaceuticals Inc.
Potential Connections via
Relationship Science
You
AVEO Pharmaceuticals Inc.
Owners & Shareholders
Details Hidden

New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements.

Details Hidden

New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements.

Recent Transactions
Details Hidden

AVEO Pharmaceuticals Inc. issued USD Common Stock

Details Hidden

AVEO Pharmaceuticals Inc. issued . USD Common Stock and Warrants

Details Hidden

AVEO Pharmaceuticals Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onAVEO Pharmaceuticals Inc. issued . USD Common Stock

Legal Advisor

Advised onAVEO Pharmaceuticals Inc. issued . USD Common Stock

Underwriter

Advised onAVEO Pharmaceuticals Inc. issued . USD Common Stock

Legal Advisor

Advised onAVEO Pharmaceuticals Inc. issued . USD Common Stock

Legal Advisor

Advised onAVEO Pharmaceuticals Inc. issued USD Common Stock

Professional

Advised onAVEO Pharmaceuticals Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Advisor

Assurance Partner at Ernst & Young LLP

Advisor

Executive Chairman of the Board & Chief Executive Officer at Strongbridge Biopharma PLC

Clients

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.

Key Stats and Financials As of 2019
Market Capitalization
$263M
Total Enterprise Value
$-22.4M
Earnings Per Share
$6.11
Net Profit
$9.39M
EBITDA
$-374K
EBITDAMargin
-1.3%
Total Debt
$15.8M
Total Equity
$14.8M
Enterprise Value / Sales
-0.78x
TEVNet Income
-2.38x
Debt TEV
-0.7x
Three Year Compounded Annual Growth Rate Of Revenue
125.38%
Five Year Compounded Annual Growth Rate Of Revenue
9.7%
Revenue
$28.8M
Non-Profit Donations & Grants
Investors
Details Hidden

Prospect Venture Partners makes investments in biomedical technology and life science private and public companies that have proven management teams, proprietary products and innovative technology or services. They provide financing for incubation, seed, first and second venture rounds and expansion capital financings of later-stage. Initial investments range from $500,000 to $10 million and $10 million to $20 million invested over the life of a company. They will serve as lead investor or as co-lead in a syndicate. They typically takes a seat on the boards of their portfolio companies.

Details Hidden

MPM invests in companies located in the US and across the globe. The firm focuses on companies that aim to revolutionize the face of medicine across multiple areas including cancer, diabetes, obesity, pain, eHealth and health technology sector. They provide financing for early stage transactions.

Details Hidden

Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations.

Suppliers
St. Vincent's Hospital Sydney Pty Ltd. Hospitals & Patient Services | Darlinghurst, Australia

St. Vincent's Hospital Sydney Pty Ltd. provides health services. It offers cardiology, dental, endocrinology, audiology, mental health, medicine, sacred heart health services, urology, and vascular surgery. The company was founded in 1857 and is headquartered in Darlinghurst, Australia.

Kyowa Kirin Co., Ltd. Chemicals | Tokyo, Japan

Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by AVEO Pharmaceuticals Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of AVEO Pharmaceuticals Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and AVEO Pharmaceuticals Inc..